Circulating free DNA (cfDNA) and tissue next-generation sequencing analysis in a phase II study of infigratinib (BGJ398) for cholangiocarcinoma with FGFR2 fusions

被引：0
|
作者：
Makawita, Shalini
Kelley, Robin Kate
Roychowdhury, Sameek
Weiss, Karl Heinz
Abou-Alfa, Ghassan K.
Macarulla, Teresa
Sadeghi, Saeed
Waldschmidt, Dirk
Zhu, Andrew X.
Goyal, Lipika
Yong, Wei-Peng
Borbath, Ivan
El-Khoueiry, Anthony B.
Philip, Philip Agop
Moran, Susan
Ye, Yining
Soifer, Harris S.
Li, Gary
Berman, Craig
Javle, Milind M.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] James Canc Hosp, Ohio State Comprehens Canc Ctr, Columbus, OH USA
[4] Univ Hosp Heidelberg, Heidelberg, Germany
[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[6] Hosp Valle De Hebron, Barcelona, Spain
[7] Univ Calif Los Angeles, Santa Monica, CA USA
[8] Klinikum Univ Koln, Cologne, Germany
[9] Massachusetts Gen Hosp, Boston, MA 02114 USA
[10] Natl Univ Canc Inst, Singapore, Singapore
[11] Clin Univ St Luc bruxelles, Brussels, Belgium
[12] USC, Kenneth Norris Comprehens Canc Ctr, Los Angeles, CA USA
[13] Karmanos Canc Inst, Detroit, MI USA
[14] QED Therapeut Inc, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
579
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions
    Javle, M.
    Kelley, R. K.
    Roychowdhury, S.
    Weiss, K. H.
    Abou-Alfa, G. K.
    Macarulla, T.
    Sadeghi, S.
    Waldschmidt, D.
    Zhu, A. X.
    Goyal, L.
    Borad, M.
    Yong, W. P.
    Borbath, I.
    El-Khoueiry, A.
    Philip, P.
    Moran, S.
    Ye, Y.
    Ising, M.
    Lewis, N.
    Bekaii-Saab, T.
    ANNALS OF ONCOLOGY, 2018, 29 : 720 - 720
  • [2] Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
    Javle, Milind
    Lowery, Maeve
    Shroff, Rachna T.
    Weiss, Karl Heinz
    Springfeld, Christoph
    Borad, Mitesh J.
    Ramanathan, Ramesh K.
    Goyal, Lipika
    Sadeghi, Saeed
    Macarulla, Teresa
    El-Khoueiry, Anthony
    Kelley, Robin Kate
    Borbath, Ivan
    Choo, Su Pin
    Oh, Do-Youn
    Philip, Philip A.
    Chen, Li-Tzong
    Reungwetwattana, Thanyanan
    Van Cutsem, Eric
    Yeh, Kun-Huei
    Ciombor, Kristen
    Finn, Richard S.
    Patel, Anuradha
    Sen, Suman
    Porter, Dale
    Isaacs, Randi
    Zhu, Andrew X.
    Abou-Alfa, Ghassan K.
    Bekaii-Saab, Tanios
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (03) : 276 - +
  • [3] Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
    Javle, Milind
    Roychowdhury, Sameek
    Kelley, Robin Kate
    Sadeghi, Saeed
    Macarulla, Teresa
    Weiss, Karl Heinz
    Waldschmidt, Dirk-Thomas
    Goyal, Lipika
    Borbath, Ivan
    El-Khoueiry, Anthony
    Borad, Mitesh J.
    Yong, Wei Peng
    Philip, Philip A.
    Bitzer, Michael
    Tanasanvimon, Surbpong
    Li, Ai
    Pande, Amit
    Soifer, Harris S.
    Shepherd, Stacie Peacock
    Moran, Susan
    Zhu, Andrew X.
    Bekaii-Saab, Tanios S.
    Abou-Alfa, Ghassan K.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (10): : 803 - 815
  • [4] Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement.
    Javle, Milind M.
    Roychowdhury, Sameek
    Kelley, Robin Kate
    Sadeghi, Saeed
    Macarulla, Teresa
    Waldschmidt, Dirk Thomas
    Goyal, Lipika
    Borbath, Ivan
    El-Khoueiry, Anthony B.
    Yong, Wei-Peng
    Philip, Philip Agop
    Bitzer, Michael
    Tanasanvimon, Suebpong
    Li Ai
    Pande, Amit
    Shepherd, Stacie Peacock
    Moran, Susan
    Abou-Alfa, Ghassan K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [5] INFIGRATINIB (BGJ398) IN PATIENTS WITH RECURRENT GLIOMAS WITH FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) ALTERATIONS: A MULTICENTER PHASE II STUDY
    Lassman, A. B.
    Sepulveda-Sanchez, J. M.
    Cloughesy, T.
    Gil-Gil, J. M.
    Puduvalli, V. K.
    Raizer, J.
    De Vos, F. Y.
    Wen, P. Y.
    Butowski, N.
    Clement, P.
    Groves, M. D.
    Belda-Iniesta, C.
    Steward, K.
    Moran, S.
    Ye, Y.
    Roth, P.
    NEURO-ONCOLOGY, 2019, 21 : 21 - 22
  • [6] INFIGRATINIB (BGJ398) IN PATIENTS WITH RECURRENT GLIOMAS WITH FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) ALTERATIONS: A MULTICENTER PHASE II STUDY
    Lassman, Andrew
    Sepulveda-Sanchez, Juan
    Cloughesy, Timothy
    Gil-Gil, Juan
    Puduvalli, Vinay
    Raizer, Jeffrey
    De Vos, Filip
    Wen, Patrick
    Butowski, Nicholas
    Clement, Paul
    Groves, Morris
    Belda-Iniesta, Cristobal
    Steward, Keith
    Rowsey, Steven
    Ye, Yining
    Roth, Patrick
    NEURO-ONCOLOGY, 2019, 21 : 20 - 20
  • [7] Analysis of tissue and circulating tumor DNA by next-generation sequencing of hepatocellular carcinoma
    Ikeda, Sadakatsu
    Lim, Jordan S.
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [8] Next-generation sequencing (NGS) of circulating cell-free DNA (cfDNA) in advanced pancreatic neuroendocrine neoplasms (PanNENs).
    Cowzer, Darren
    Shah, Ronak H.
    Punn, Sippy
    Fiedler, Laura
    DeMore, April
    Chou, Joanne F.
    Capanu, Marinela
    Berger, Michael F.
    Reidy-Lagunes, Diane
    Raj, Nitya Prabhakar
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 653 - 653
  • [9] A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy.
    Javle, Milind M.
    Shroff, Rachna T.
    Zhu, Andrew
    Sadeghi, Saeed
    Choo, Supin
    Borad, Mitesh J.
    Lowery, Maeve Aine
    El-Khoueiry, Anthony
    Macarulla, Teresa
    Philip, Agop Philip
    Oh, Do-Youn
    Van Cutsem, Eric
    Yeh, Kun-Huei
    Isaacs, Randi
    McGarry, Carolyn
    Sen, Suman
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [10] Circulating cell-free tumor DNA (cfDNA) analysis of 50-genes by next-generation sequencing (NGS) in the prospective MOSCATO trial
    Ileana, Ecaterina
    Jovelet, Cecile
    Le Deley, Marie-Cecile
    Massard, Christophe
    Motte, Nelly
    Hollebecque, Antoine
    Boichard, Amelie
    Ferte, Charles
    Postel-Vinay, Sophie
    Rosellini, Silvia
    Ngo-Camus, Maud
    De Baere, Thierry
    Vielh, Philippe
    Richon, Catherine
    Laporte, Melanie
    Gouissem, Siham
    Loriot, Yohann
    Bahleda, Rastilav
    Gazzah, Anas
    Varga, Andrea
    Vassal, Gilles
    Eggermont, Alexander
    Andre, Fabrice
    Soria, Jean-Charles
    Lacroix, Ludovic
    CANCER RESEARCH, 2015, 75
12345